Here's what you should think about before rolling this hot new technology into your business. Photo via Getty Images

The world has been captivated by ChatGPT, an artificial intelligence program that can understand and respond to questions and statements using natural language, just like humans. It has been trained on a large amount of text data and uses this knowledge to generate helpful and informative responses to users.

As great and resourceful as this can be, there are some major aspects about it that can be harmful in a business setting, such as the inability to make personal connections. A sales manager using AI to write sales scripts cannot incorporate the emotional intelligence needed to form a connection. With the switch to AI and loss of this personal touch, the company’s close rate drops significantly, and the sales manager’s effort to find solution may just be to run more numbers in terms of contacts and sales attempts, which usually exacerbates the problem.

Another example of how ChatGPT can hurt your business is by relying on it to generate website and social media content. A business owner that believes ChatGPT will do the “heavy lifting” and grow his or her business is overlooking the importance of creating real and experiential marketing experiences for customers. Business owners can inadvertently spend entire budgets on AI driven social media ands and not have the sales numbers to cover these costs due to their low returns on investments for many industries and keep the business in operation.

The overarching theme, or danger behind ChatGPT, is that people are relying heavily on it to produce their work. After all, relying on technology is part of our human nature. When great technology is introduced, such as email, teleconferencing, AI assisted searching, etc., we rarely ask ‘how can this technology assist me?’ versus ‘how can this technology do things for me?’ The greater the technology, the greater likelihood humans will take the easiest path.

ChatGPT not only affects businesses, but it also applies to education. Teachers are already seeing a drop in math skills as kids carry around calculators. Just wait until next semester when educators are reading thousands of essays written by ChatGPT.

Just as we would hate to see our children deprive themselves of actual skills, the same can be said for our business people. Some of the main issues that arise from the use of ChatGPT are:

Diminishing Rates of Return

When we embrace technology to the point that we no longer put forth effort from a practiced skill set, we can expect to see declining engagement rates, click-through rates and customer loyalty. As of 2023, the online engagement rate has fallen from 5% to 0.06%. Click-through rates are not faring much better with a measly 6.3%. As these numbers continue to fall (which they have every year for the past couple decades now), we continue to just brush it off as this is how business is done.

Aversion in the Marketplace

People are becoming so displeased with technology driven processes (as opposed to technology assisted processes) that they have a strong aversion to companies using it. How many social media ads have prompted you to make a purchase? How many times do you provide a bogus email to a website form? When doing a search, how many times do you scroll to the bottom without looking and hit page two because you know you are not getting any real results on the first page anymore?

Yes, ChatGPT is cool and yes, there are some amazing uses you can implement into your business; however, do not look at it as the answer to any and all business problems. Embrace your craft as a leader and avoid subbing the work out to tech - doing so could cost you everything.

As a business owner myself, I am not opposed to technology. I am all in favor of what technology can do. However, there is no denying that the more we look to technology to do the work for us instead of with us, the more we see a drastic decline in the overall skill set of business people without an increase in business success rates.

------

Josh Tolley is the founder of Kingsbridge LLC and is based in Houston.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.